PMID- 12166542
OWN - NLM
STAT- MEDLINE
DCOM- 20020927
LR  - 20220409
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 56
IP  - 6
DP  - 2002 Jul-Aug
TI  - A multinational, randomised, 12-week, comparative study of donepezil and 
      rivastigmine in patients with mild to moderate Alzheimer's disease.
PG  - 441-6
AB  - This 12-week, multinational study compared the tolerability and cognitive effects 
      of donepezil (up to 10 mg once daily) and rivastigmine (up to 6 mg twice daily) 
      in 111 patients with mild to moderate Alzheimer's disease. Both medications were 
      administered open label according to recommended dosing regimens from the 
      respective product labelling available during the conduct of the study. More 
      patients in the donepezil group (89.3%) completed the study compared with the 
      rivastigmine group (69.1%; p=0.009), and 10.7% of the donepezil group and 21.8% 
      of the rivastigmine group discontinued due to adverse events (AEs); 87.5% of 
      donepezil-treated patients and 47.3% of rivastigmine-treated patients remained on 
      the maximum approved dose of each drug at the last study visit. Both groups 
      showed comparable improvements on the ADAS-cog administered by raters blind to 
      study medication at weeks 4 and 12. Thus, using the recommended dosing schedules, 
      donepezil was better tolerated with fewer discontinuations due to AEs, and both 
      agents improved cognition to a similar extent.
FAU - Wilkinson, D G
AU  - Wilkinson DG
AD  - Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK.
FAU - Passmore, A P
AU  - Passmore AP
FAU - Bullock, R
AU  - Bullock R
FAU - Hopker, S W
AU  - Hopker SW
FAU - Smith, R
AU  - Smith R
FAU - Potocnik, F C V
AU  - Potocnik FC
FAU - Maud, C M
AU  - Maud CM
FAU - Engelbrecht, I
AU  - Engelbrecht I
FAU - Hock, C
AU  - Hock C
FAU - Ieni, J R
AU  - Ieni JR
FAU - Bahra, R S
AU  - Bahra RS
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Carbamates)
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0 (Indans)
RN  - 0 (Phenylcarbamates)
RN  - 0 (Piperidines)
RN  - 8SSC91326P (Donepezil)
RN  - PKI06M3IW0 (Rivastigmine)
SB  - IM
CIN - Int J Clin Pract. 2002 Jul-Aug;56(6):414-5. PMID: 12166537
CIN - Int J Clin Pract. 2003 Jan-Feb;57(1):70-1; author reply 71. PMID: 12587950
CIN - Int J Clin Pract. 2003 Jun;57(5):449; author reply 449. PMID: 12846358
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/*drug therapy
MH  - Analysis of Variance
MH  - Carbamates/*therapeutic use
MH  - Cholinesterase Inhibitors/*therapeutic use
MH  - Donepezil
MH  - Female
MH  - Humans
MH  - Indans/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - *Phenylcarbamates
MH  - Piperidines/*therapeutic use
MH  - Rivastigmine
MH  - Treatment Outcome
EDAT- 2002/08/09 10:00
MHDA- 2002/09/28 04:00
CRDT- 2002/08/09 10:00
PHST- 2002/08/09 10:00 [pubmed]
PHST- 2002/09/28 04:00 [medline]
PHST- 2002/08/09 10:00 [entrez]
PST - ppublish
SO  - Int J Clin Pract. 2002 Jul-Aug;56(6):441-6.